Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
hautnah
Erschienen in:

15.07.2022 | Originalien

Hidradenitis suppurativa

verfasst von: Dr. Antonia Wiala, Theresa Stockinger, Christian Posch, Klemens Rappersberger

Erschienen in: hautnah | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Hidradenitis suppurativa (HS, Acne inversa) ist eine chronisch entzündliche Hauterkrankung, gekennzeichnet durch das rezidivierende Auftreten von entzündlichen Knoten, Abszessen und Fisteln in den intertriginösen Arealen. Schmerzen und putride übelriechende Sekretion führen zu massiven Einschränkungen der Lebensqualität. Die follikuläre Okklusion scheint in der multifaktoriellen Pathogenese der Erkrankung eine wichtige Rolle zu spielen. Zudem sind genetische Prädispositionen und zahlreiche Triggerfaktoren wie Übergewicht und Tabakkonsum bekannt. Die Diagnose der HS wird klinisch anhand der charakteristischen Hautveränderungen gestellt. Zur Einteilung der Schweregrade dient unter anderem das Hurley-Staging. Therapeutische Optionen bei milder HS umfassen eine antiseptische sowie antibiotische Lokaltherapie. Bei milder bis moderater Erkrankung kann durch systemische antibiotische Therapien (Kombination Clindamycin-Rifampicin; Tetracycline) eine vorrübergehende Remission erreicht werden. Zur Behandlung der moderaten bis schweren HS ist Adalimumab, ein TNF-α-Antagonist, zugelassen. Operative Techniken spielen eine wichtige Rolle bei der Behandlung von Fistelgängen und Narbensträngen. Mittels En-bloc-Resektion, also der großzügigen Exzision erkrankter Hautareale, kann die Heilung eines umschriebenen Areals erreicht werden. Hauptziel aktueller Therapien bleibt eine verbesserte Lebensqualität.
Vorheriger Artikel Simpler Farbtest für extragenitalen Lichen sclerosus
Nächster Artikel Mastozytose
Literatur
1.
Saunte DML, Jemec GBE (2017) Hidradenitis suppurativa: advances in diagnosis and treatment. JAMA 318:2019–2032PubMedCrossRef
2.
Revuz JE, Canoui-Poitrine F, Wolkenstein P, Viallette C, Gabison G, Pouget F, Poli F, Faye O, Roujeau JC, Bonnelye G, Grob JJ, Bastuji-Garin S (2008) Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol 59:596–601PubMedCrossRef
3.
Jemec GB, Heidenheim M, Nielsen NH (1996) The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol 35:191–194PubMedCrossRef
4.
Vaiopoulos AG, Nikolakis G, Zouboulis CC (2020) Hidradenitis suppurativa in paediatric patients: a retrospective monocentric study in Germany and review of the literature. J Eur Acad Dermatol Venereol 34:2140–2146PubMedCrossRef
5.
Tilles G (2006) Verneuil and Verneuil’s disease: an historical overview. In: Jemec GBE, Revuz J, Leyden JJ (Hrsg) Hidradenitis suppurativa. Springer, Berlin, Heidelberg, S 4–10CrossRef
6.
Pink A, Anzengruber F, Navarini AA (2018) Acne and hidradenitis suppurativa. Br J Dermatol 178:619–631PubMedCrossRef
7.
Yu CC, Cook MG (1990) Hidradenitis suppurativa: a disease of follicular epithelium, rather than apocrine glands. Br J Dermatol 122:763–769PubMedCrossRef
8.
van der Zee HH, de Ruiter L, van den Broecke DG, Dik WA, Laman JD, Prens EP (2011) Elevated levels of tumour necrosis factor (TNF)-alpha, interleukin (IL)-1beta and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-alpha and IL-1beta. Br J Dermatol 164:1292–1298PubMedCrossRef
9.
Sabat R, Grutz G, Warszawska K, Kirsch S, Witte E, Wolk K, Geginat J (2010) Biology of interleukin-10. Cytokine Growth Factor Rev 21:331–344PubMedCrossRef
10.
Wolk K, Warszawska K, Hoeflich C, Witte E, Schneider-Burrus S, Witte K, Kunz S, Buss A, Roewert HJ, Krause M, Lukowsky A, Volk HD, Sterry W, Sabat R (2011) Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa. J Immunol 186:1228–1239PubMedCrossRef
11.
Jimenez-Gallo D, de la Varga-Martinez R, Ossorio-Garcia L, Albarran-Planelles C, Rodriguez C, Linares-Barrios M (2017) The clinical significance of increased serum proinflammatory cytokines, C‑reactive protein, and erythrocyte sedimentation rate in patients with hidradenitis suppurativa. Mediators Inflamm 2017:2450401PubMedPubMedCentralCrossRef
12.
13.
von der Werth JM, Williams HC (2000) The natural history of hidradenitis suppurativa. J Eur Acad Dermatol Venereol 14:389–392PubMedCrossRef
14.
Wang B, Yang W, Wen W, Sun J, Su B, Liu B, Ma D, Lv D, Wen Y, Qu T, Chen M, Sun M, Shen Y, Zhang X (2010) Gamma-secretase gene mutations in familial acne inversa. Science 330:1065PubMedCrossRef
15.
Frew JW, Vekic DA, Woods J, Cains GD (2017) A systematic review and critical evaluation of reported pathogenic sequence variants in hidradenitis suppurativa. Br J Dermatol 177:987–998PubMedCrossRef
16.
Wang Z, Yan Y, Wang B (2021) Gamma-secretase genetics of hidradenitis suppurativa: a systematic literature review. Dermatology 237:698–704PubMedCrossRef
17.
Canoui-Poitrine F, Le Thuaut A, Revuz JE, Viallette C, Gabison G, Poli F, Pouget F, Wolkenstein P, Bastuji-Garin S (2013) Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross-sectional study. J Invest Dermatol 133:1506–1511PubMedCrossRef
18.
Ingram JR, Wood M, John B, Butler R, Anstey AV (2013) Absence of pathogenic gamma-secretase mutations in a South Wales cohort of familial and sporadic hidradenitis suppurativa (acne inversa). Br J Dermatol 168:874–876PubMedCrossRef
19.
Nikolakis G, Kaleta KP, Vaiopoulos AG, Wolter K, Baroud S, Wojas-Pelc A, Zouboulis CC (2021) Phenotypes and pathophysiology of syndromic hidradenitis suppurativa: different faces of the same disease? A systematic review. Dermatology 237:673–697PubMedCrossRef
20.
Guet-Revillet H, Jais JP, Ungeheuer MN, Coignard-Biehler H, Duchatelet S, Delage M, Lam T, Hovnanian A, Lortholary O, Nassif X, Nassif A, Join-Lambert O (2017) The microbiological landscape of anaerobic infections in hidradenitis suppurativa: a prospective metagenomic study. Clin Infect Dis 65:282–291PubMedCrossRef
21.
Nikolakis G, Join-Lambert O, Karagiannidis I, Guet-Revillet H, Zouboulis CC, Nassif A (2015) Bacteriology of hidradenitis suppurativa/acne inversa: a review. J Am Acad Dermatol 73:S12–8PubMedCrossRef
22.
Ring HC, Bay L, Nilsson M, Kallenbach K, Miller IM, Saunte DM, Bjarnsholt T, Tolker-Nielsen T, Jemec GB (2017) Bacterial biofilm in chronic lesions of hidradenitis suppurativa. Br J Dermatol 176:993–1000PubMedCrossRef
23.
Konig A, Lehmann C, Rompel R, Happle R (1999) Cigarette smoking as a triggering factor of hidradenitis suppurativa. Dermatology 198:261–264PubMedCrossRef
24.
Hana A, Booken D, Henrich C, Gratchev A, Maas-Szabowski N, Goerdt S, Kurzen H (2007) Functional significance of non-neuronal acetylcholine in skin epithelia. Life Sci 80:2214–2220PubMedCrossRef
25.
Wittebole X, Hahm S, Coyle SM, Kumar A, Calvano SE, Lowry SF (2007) Nicotine exposure alters in vivo human responses to endotoxin. Clin Exp Immunol 147:28–34PubMedPubMedCentralCrossRef
26.
Wolk K, Join-Lambert O, Sabat R (2020) Aetiology and pathogenesis of hidradenitis suppurativa. Br J Dermatol 183:999–1010PubMedCrossRef
27.
Karagiannidis I, Nikolakis G, Zouboulis CC (2016) Endocrinologic aspects of hidradenitis suppurativa. Dermatol Clin 34:45–49PubMedCrossRef
28.
Vossen AR, van Straalen KR, Prens EP, van der Zee HH (2017) Menses and pregnancy affect symptoms in hidradenitis suppurativa: a cross-sectional study. J Am Acad Dermatol 76:155–156PubMedCrossRef
29.
Lyons AB, Peacock A, McKenzie SA, Jacobsen G, Naik HB, Shi VY, Hamzavi IH, Hsiao JL (2020) Evaluation of hidradenitis suppurativa disease course during pregnancy and postpartum. JAMA Dermatol 156:681–685PubMedCrossRef
30.
Garg A, Neuren E, Strunk A (2018) Hidradenitis suppurativa is associated with polycystic ovary syndrome: a population-based analysis in the United States. J Invest Dermatol 138:1288–1292PubMedCrossRef
31.
Schrader AM, Deckers IE, van der Zee HH, Boer J, Prens EP (2014) Hidradenitis suppurativa: a retrospective study of 846 Dutch patients to identify factors associated with disease severity. J Am Acad Dermatol 71:460–467PubMedCrossRef
32.
Boer J (2017) Should hidradenitis suppurativa be included in dermatoses showing koebnerization? Is it friction or fiction? Dermatology 233:47–52PubMedCrossRef
33.
Attanoos RL, Appleton MA, Douglas-Jones AG (1995) The pathogenesis of hidradenitis suppurativa: a closer look at apocrine and apoeccrine glands. Br J Dermatol 133:254–258PubMedCrossRef
34.
Jemec GB, Kimball AB (2015) Hidradenitis suppurativa: epidemiology and scope of the problem. J Am Acad Dermatol 73:S4–7PubMedCrossRef
35.
Ovadja ZN, Schuit MM, van der Horst C, Lapid O (2019) Inter- and intrarater reliability of Hurley staging for hidradenitis suppurativa. Br J Dermatol 181:344–349PubMedPubMedCentralCrossRef
36.
Sartorius K, Emtestam L, Jemec GB, Lapins J (2009) Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol 161:831–839PubMedCrossRef
37.
Kimball AB, Kerdel F, Adams D, Mrowietz U, Gelfand JM, Gniadecki R, Prens EP, Schlessinger J, Zouboulis CC, van der Zee HH, Rosenfeld M, Mulani P, Gu Y, Paulson S, Okun M, Jemec GB (2012) Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med 157:846–855PubMedCrossRef
38.
Zouboulis CC, Tzellos T, Kyrgidis A, Jemec GBE, Bechara FG, Giamarellos-Bourboulis EJ, Ingram JR, Kanni T, Karagiannidis I, Martorell A, Matusiak L, Pinter A, Prens EP, Presser D, Schneider-Burrus S, von Stebut E, Szepietowski JC, van der Zee HH, Wilden SM, Sabat R, European Hidradenitis Suppurativa Foundation Investigator Group (2017) Development and validation of the international hidradenitis suppurativa severity score system (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol 177:1401–1409PubMedCrossRef
39.
Shlyankevich J, Chen AJ, Kim GE, Kimball AB (2014) Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis. J Am Acad Dermatol 71:1144–1150PubMedCrossRef
40.
Sabat R, Chanwangpong A, Schneider-Burrus S, Metternich D, Kokolakis G, Kurek A, Philipp S, Uribe D, Wolk K, Sterry W (2012) Increased prevalence of metabolic syndrome in patients with acne inversa. PLoS One 7:e31810PubMedPubMedCentralCrossRef
41.
Gold DA, Reeder VJ, Mahan MG, Hamzavi IH (2014) The prevalence of metabolic syndrome in patients with hidradenitis suppurativa. J Am Acad Dermatol 70:699–703PubMedCrossRef
42.
Egeberg A, Gislason GH, Hansen PR (2016) Risk of major adverse cardiovascular events and all-cause mortality in patients with hidradenitis suppurativa. JAMA Dermatol 152:429–434PubMedCrossRef
43.
Schneider-Burrus S, Witte-Haendel E, Christou D, Rigoni B, Sabat R, Diederichs G (2016) High prevalence of back pain and axial spondyloarthropathy in patients with hidradenitis suppurativa. Dermatology 232:606–612PubMedCrossRef
44.
Richette P, Molto A, Viguier M, Dawidowicz K, Hayem G, Nassif A, Wendling D, Aubin F, Liote F, Bachelez H (2014) Hidradenitis suppurativa associated with spondyloarthritis—results from a multicenter national prospective study. J Rheumatol 41:490–494PubMedCrossRef
45.
Deckers IE, Benhadou F, Koldijk MJ, Del Marmol V, Horvath B, Boer J, van der Zee HH, Prens EP (2017) Inflammatory bowel disease is associated with hidradenitis suppurativa: results from a multicenter cross-sectional study. J Am Acad Dermatol 76:49–53PubMedCrossRef
46.
van der Zee HH, de Winter K, van der Woude CJ, Prens EP (2014) The prevalence of hidradenitis suppurativa in 1093 patients with inflammatory bowel disease. Br J Dermatol 171:673–675PubMedCrossRef
47.
Frings VG, Bauer B, Gloditzsch M, Goebeler M, Presser D (2019) Assessing the psychological burden of patients with hidradenitis suppurativa. Eur J Dermatol 29:294–301PubMed
48.
Sampogna F, Fania L, Mastroeni S, Fusari R, Napolitano M, Ciccone D, Mazzanti C, Pallotta S, Panebianco A, Abeni D (2020) Correlation between depression, quality of life and clinical severity in patients with hidradenitis suppurativa. Acta Derm Venereol 100:adv319PubMedCrossRef
49.
Patel KR, Lee HH, Rastogi S, Vakharia PP, Hua T, Chhiba K, Singam V, Silverberg JI (2020) Association between hidradenitis suppurativa, depression, anxiety, and suicidality: a systematic review and meta-analysis. J Am Acad Dermatol 83:737–744PubMedCrossRef
50.
Cugno M, Borghi A, Marzano AV (2017) PAPA, PASH and PAPASH syndromes: pathophysiology, presentation and treatment. Am J Clin Dermatol 18:555–562PubMedCrossRef
51.
Hessam S, Sand M, Gambichler T, Bechara FG (2015) Correlation of inflammatory serum markers with disease severity in patients with hidradenitis suppurativa (HS). J Am Acad Dermatol 73:998–1005PubMedCrossRef
52.
Wortsman X, Moreno C, Soto R, Arellano J, Pezo C, Wortsman J (2013) Ultrasound in-depth characterization and staging of hidradenitis suppurativa. Dermatol Surg 39:1835–1842PubMedCrossRef
53.
Virgilio E, Bocchetti T, Balducci G (2015) Utility of MRI in the diagnosis and post-treatment evaluation of anogenital hidradenitis suppurativa. Dermatol Surg 41:865–866PubMedCrossRef
54.
von der Werth JM, Jemec GB (2001) Morbidity in patients with hidradenitis suppurativa. Br J Dermatol 144:809–813PubMedCrossRef
55.
Matusiak L, Bieniek A, Szepietowski JC (2010) Psychophysical aspects of hidradenitis suppurativa. Acta Derm Venereol 90:264–268PubMedCrossRef
56.
Matusiak L, Szczech J, Kaaz K, Lelonek E, Szepietowski JC (2018) Clinical characteristics of pruritus and pain in patients with hidradenitis suppurativa. Acta Derm Venereol 98:191–194PubMedCrossRef
57.
Cuenca-Barrales C, Montero-Vilchez T, Szepietowski JC, Matusiak L, Molina-Leyva A (2021) Sexual impairment in patients with hidradenitis suppurativa: a systematic review. J Eur Acad Dermatol Venereol 35:345–352PubMedCrossRef
58.
Janse IC, Deckers IE, van der Maten AD, Evers AWM, Boer J, van der Zee HH, Prens EP, Horvath B (2017) Sexual health and quality of life are impaired in hidradenitis suppurativa: a multicentre cross-sectional study. Br J Dermatol 176:1042–1047PubMedCrossRef
59.
Theut Riis P, Thorlacius L, Knudsen List E, Jemec GBE (2017) A pilot study of unemployment in patients with hidradenitis suppurativa in Denmark. Br J Dermatol 176:1083–1085PubMedCrossRef
60.
Matusiak L, Bieniek A, Szepietowski JC (2010) Hidradenitis suppurativa markedly decreases quality of life and professional activity. J Am Acad Dermatol 62:706–708PubMedCrossRef
61.
62.
Micieli R, Alavi A (2018) Lymphedema in patients with hidradenitis suppurativa: a systematic review of published literature. Int J Dermatol 57:1471–1480PubMedCrossRef
63.
Deckers IE, van der Zee HH, Prens EP (2016) Severe fatigue based on anaemia in patients with hidradenitis suppurativa: report of two cases and a review of the literature. J Eur Acad Dermatol Venereol 30:174–175PubMedCrossRef
64.
65.
Chapman S, Delgadillo D III, Barber C, Khachemoune A (2018) Cutaneous squamous cell carcinoma complicating hidradenitis suppurativa: a review of the prevalence, pathogenesis, and treatment of this dreaded complication. Acta Dermatovenerol Alp Pannonica Adriat 27:25–28PubMed
66.
Zouboulis CC, Desai N, Emtestam L, Hunger RE, Ioannides D, Juhasz I, Lapins J, Matusiak L, Prens EP, Revuz J, Schneider-Burrus S, Szepietowski JC, van der Zee HH, Jemec GB (2015) European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol 29:619–644PubMedCrossRef
67.
Ingram JR, Collier F, Brown D, Burton T, Burton J, Chin MF, Desai N, Goodacre TEE, Piguet V, Pink AE, Exton LS, Mohd Mustapa MF (2019) British association of dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol 180:1009–1017PubMedCrossRef
68.
Alikhan A, Sayed C, Alavi A, Alhusayen R, Brassard A, Burkhart C, Crowell K, Eisen DB, Gottlieb AB, Hamzavi I, Hazen PG, Jaleel T, Kimball AB, Kirby J, Lowes MA, Micheletti R, Miller A, Naik HB, Orgill D, Poulin Y (2019) North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian hidradenitis suppurativa foundations: part I: diagnosis, evaluation, and the use of complementary and procedural management. J Am Acad Dermatol 81:76–90PubMedPubMedCentralCrossRef
69.
Alikhan A, Sayed C, Alavi A, Alhusayen R, Brassard A, Burkhart C, Crowell K, Eisen DB, Gottlieb AB, Hamzavi I, Hazen PG, Jaleel T, Kimball AB, Kirby J, Lowes MA, Micheletti R, Miller A, Naik HB, Orgill D, Poulin Y (2019) North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian hidradenitis suppurativa foundations: part II: topical, intralesional, and systemic medical management. J Am Acad Dermatol 81:91–101PubMedPubMedCentralCrossRef
70.
Dauden E, Lazaro P, Aguilar MD, Blasco AJ, Suarez C, Marin I, Queiro R, Bassas-Vila J, Martorell A, Garcia-Campayo J (2018) Recommendations for the management of comorbidity in hidradenitis suppurativa. J Eur Acad Dermatol Venereol 32:129–144PubMedCrossRef
71.
Clemmensen OJ (1983) Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol 22:325–328PubMedCrossRef
72.
Fischer AH, Haskin A, Okoye GA (2017) Patterns of antimicrobial resistance in lesions of hidradenitis suppurativa. J Am Acad Dermatol 76:309–13.e2PubMedCrossRef
73.
Riis PT, Boer J, Prens EP, Saunte DM, Deckers IE, Emtestam L, Sartorius K, Jemec GB (2016) Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): a case series. J Am Acad Dermatol 75:1151–1155PubMedCrossRef
74.
Mendonca CO, Griffiths CE (2006) Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. Br J Dermatol 154:977–978PubMedCrossRef
75.
van Straalen KR, Tzellos T, Guillem P, Benhadou F, Cuenca-Barrales C, Daxhelet M, Daoud M, Efthymiou O, Giamarellos-Bourboulis EJ, Jemec GBE, Katoulis AC, Koenig A, Lazaridou E, Marzano AV, Matusiak L, Molina-Leyva A, Moltrasio C, Pinter A, Potenza C, Romani J, Saunte DM, Skroza N, Stergianou D, Szepietowski J, Trigoni A, Vilarrasa E, van der Zee HH (2021) The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: results of a prospective European cohort study. J Am Acad Dermatol 85:369–378PubMedCrossRef
76.
Join-Lambert O, Coignard H, Jais JP, Guet-Revillet H, Poiree S, Fraitag S, Jullien V, Ribadeau-Dumas F, Theze J, Le Guern AS, Behillil S, Lefleche A, Berche P, Consigny PH, Lortholary O, Nassif X, Nassif A (2011) Efficacy of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa. Dermatology 222:49–58PubMedCrossRef
77.
Join-Lambert O, Coignard-Biehler H, Jais JP, Delage M, Guet-Revillet H, Poiree S, Duchatelet S, Jullien V, Hovnanian A, Lortholary O, Nassif X, Nassif A (2016) Efficacy of ertapenem in severe hidradenitis suppurativa: a pilot study in a cohort of 30 consecutive patients. J Antimicrob Chemother 71:513–520PubMedCrossRef
78.
Yazdanyar S, Boer J, Ingvarsson G, Szepietowski JC, Jemec GB (2011) Dapsone therapy for hidradenitis suppurativa: a series of 24 patients. Dermatology 222:342–346PubMedCrossRef
79.
Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, Armstrong AW, Kerdel F, Gold MH, Forman SB, Korman NJ, Giamarellos-Bourboulis EJ, Crowley JJ, Lynde C, Reguiai Z, Prens EP, Alwawi E, Mostafa NM, Pinsky B, Sundaram M, Gu Y, Carlson DM, Jemec GB (2016) Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med 375:422–434PubMedCrossRef
80.
Zouboulis CC, Okun MM, Prens EP, Gniadecki R, Foley PA, Lynde C, Weisman J, Gu Y, Williams DA, Jemec GBE (2019) Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3‑year results of a phase 3 open-label extension study. J Am Acad Dermatol 80:60–69.e2PubMedCrossRef
81.
Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA (2010) Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol 62:205–217PubMedCrossRef
82.
Ghias MH, Johnston AD, Kutner AJ, Micheletti RG, Hosgood HD, Cohen SR (2020) High-dose, high-frequency infliximab: a novel treatment paradigm for hidradenitis suppurativa. J Am Acad Dermatol 82:1094–1101PubMedCrossRef
83.
Janse I, Bieniek A, Horvath B, Matusiak L (2016) Surgical procedures in hidradenitis suppurativa. Dermatol Clin 34:97–109PubMedCrossRef
84.
Posch C, Monshi B, Quint T, Vujic I, Lilgenau N, Rappersberger K (2017) The role of wide local excision for the treatment of severe hidradenitis suppurativa (Hurley grade III): retrospective analysis of 74 patients. J Am Acad Dermatol 77:123–29.e5PubMedCrossRef
85.
Harrison BJ, Mudge M, Hughes LE (1987) Recurrence after surgical treatment of hidradenitis suppurativa. Br Med J (Clin Res Ed) 294:487–489CrossRef
86.
Morgan WP, Harding KG, Hughes LE (1983) A comparison of skin grafting and healing by granulation, following axillary excision for hidradenitis suppurativa. Ann R Coll Surg Engl 65:235–236PubMedPubMedCentral
87.
van der Zee HH, Prens EP, Boer J (2010) Deroofing: a tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions. J Am Acad Dermatol 63:475–480PubMedCrossRef
88.
Tierney E, Mahmoud BH, Hexsel C, Ozog D, Hamzavi I (2009) Randomized control trial for the treatment of hidradenitis suppurativa with a neodymium-doped yttrium aluminium garnet laser. Dermatol Surg 35:1188–1198PubMedCrossRef
Metadaten
Titel
Hidradenitis suppurativa
verfasst von
Dr. Antonia Wiala
Theresa Stockinger
Christian Posch
Klemens Rappersberger
Publikationsdatum
15.07.2022
Verlag
Springer Vienna
Erschienen in
hautnah / Ausgabe 3/2022
Print ISSN: 1866-2250
Elektronische ISSN: 2192-6484
DOI
https://doi.org/10.1007/s12326-022-00518-1

Weitere Artikel der Ausgabe 3/2022

Erkennen Sie eine Nahrungsmittelallergie bei Kindern?

  • aktuell

Sind es Affenpocken? So klären Sie Verdachtsfälle ab

  • aktuell

Studie legt Grundstein für neue Behandlungsstrategie

  • aktuell

UV-B-Bestrahlung in der COVID-​Therapie

  • aktuell

Chronischer Juckreiz bei jedem siebten Schulkind

  • aktuell

Bei Spaltnägeln vor allem an Tumoren denken!

  • aktuell